Revefenacin
1 NDC across 1 manufacturer|0 Generic,1 Brand
Revefenacin is used to treat chronic obstructive pulmonary disease, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Nov 9, 2018. In 2024, Medicare Part D spent $7 million on Revefenacin across 5,673 claims for 1,636 beneficiaries.
Revefenacin is available as 1 NDC from 1 manufacturer (0 generic, 1 brand), with NADAC prices from $17.42 to $17.42 per ML. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
1
0G / 1B
Manufacturers
1
competing in market
Price Spread
$17.42 – $17.42
per ML
7d Activity
avg -0.3% WoW · of 1 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
1 manufacturer producing REVEFENACIN
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
YUPELRI 175 MCG/3 ML SOLUTION | $17.4196 per ML | -0.30% |
Frequently Asked Questions
What is Revefenacin used to treat?
Revefenacin is used to treat chronic obstructive pulmonary disease, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Revefenacin?
In 2024, Medicare Part D spent $7 million on Revefenacin across 5,673 claims for 1,636 beneficiaries.
How many Revefenacin products are on the market?
The Revefenacin drug market contains 1 NDC from 1 manufacturer — 0 generic and 1 brand product.
What is the price range for Revefenacin?
NADAC reference prices for Revefenacin range from $17.4196 to $17.4196 per ML.
Which manufacturers make Revefenacin?
1 manufacturer lists Revefenacin in NADAC. Ranked by number of NDCs, the largest are Viatris Specialty LLC (1).
How has the price of Revefenacin changed recently?
Over the past 7 days, 0 Revefenacin NDCs rose and 1 fell, with a market-wide average change of -0.3%.